Pharma Industry News

Gilead Treatment for PBC Granted EC Conditional Marketing Authorization

13 hours ago
Add Comment
by David Miller
945 Views

Seladelpar, which is marketed in the US as Livdelzi, was recommended for an orphan drug designation by CHMP in December 2024.

Seladelpar, which is marketed in the US as Livdelzi, was recommended for an orphan drug designation by CHMP in December 2024.

You may also like

About the author

David Miller

a pharmacist, a tech enthusiastic, who explored the Internet to gather all latest information pharma, biotech, healthcare and other related industries.

View all posts

Leave a Comment

Don`t Leave Yet!

Thank you!

[mwai_chat window="true" fullscreen="true"]